
Pharmacally
Disease & Drugs
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Disease & Drugs
Clinical TrialsEnlivex Reports 79.2% Allocetra Response in Older Knee OA PatientsEnlivex reported 12-month Phase IIa results for Allocetra in knee osteoarthritis, with 79.2% of patients aged 64 and older achieving a clinically meaningful response compared with 47.6% receiving…Fact-Checked
Clinical TrialsLilly’s AtaiBeckley Reports Positive Mebufotenin Results in Depression TrialAtaiBeckley’s investigational intranasal mebufotenin, based on 5-MeO-DMT, a naturally occurring psychedelic found in Sonoran Desert toad secretions, demonstrated significant antidepressant effects in a 193-participant Phase 2b trial.Fact-Checked
Clinical TrialsInventisBio’s D-2570 Delivers Up to 90% PASI 75 Response in Psoriasis TrialInventisBio’s oral TYK2 inhibitor D-2570 demonstrated significant improvements in PASI 75, PASI 90 and PASI 100 responses in a Phase 2 trial involving patients with moderate-to-severe plaque psoriasis.…Fact-Checked
Clinical TrialsAtom’s Lingdolinurad Delivers Strong Phase 2b Gout ResultsAtom Therapeutics’ lingdolinurad achieved higher serum urate target attainment than febuxostat in a Phase 2b gout study, with 91.9% of patients reaching the primary urate target at Week…Fact-Checked
Clinical TrialsAbbott Reports Strong TECTONIC Results for SonicForce IVLAbbott’s pivotal TECTONIC trial met both primary endpoints, reporting 97% procedural success and a 0.3% 30-day target lesion failure rate with its investigational SonicForce coronary intravascular lithotripsy system.…Fact-Checked
Drugs Safety AlertEMA Flags Deanxit Risks and Batch-Linked Immunoglobulin ReactionsThe EMA’s PRAC has initiated a safety review of Deanxit following reports of persistent neurological and psychiatric effects.Fact-Checked
New Drug ApprovalMHRA Conditionally Authorises Ultragenyx’s Dojolvi for LC-FAODThe MHRA has granted conditional marketing authorisation to Ultragenyx’s triheptanoin (Dojolvi) for adults and children with long-chain fatty acid oxidation disorders (LC-FAOD).Fact-Checked
New Drug ApprovalINOVIO Wins FDA Approval for VOCERYQ to Reduce RRP SurgeriesINOVIO’s VOCERYQ receives FDA accelerated approval as the first plasmid DNA-based immunotherapy in the United States, offering adults with recurrent respiratory papillomatosis a new approach to reducing repeated…Fact-Checked
Clinical TrialsAer Therapeutics Reports Phase 2a Failure for Fexlamose in COPDAer Therapeutics’ investigational therapy fexlamose failed to meet its Phase 2a efficacy endpoints in moderate-to-severe COPD, showing no improvement in pulmonary function or overall mucus-plug burden after 28…Fact-Checked
Clinical TrialsRegeneron’s Libtayo Maintains DFS Benefit in Longer-Term C-POST ResultsLonger-term Phase 3 C-POST findings showed sustained disease-free survival benefit with adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma.Fact-Checked
New Drug ApprovalVertex Expands Casgevy Approval to Children Aged Five in the UKThe MHRA has extended the UK authorisation of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) to children aged five and older with severe sickle cell disease and transfusion-dependent β-thalassemia, lowering…Fact-Checked
Clinical TrialsSobi Reports Positive REDUCE-2 Results for PozdeutinuradSobi’s Phase 3 REDUCE-2 study found that pozdeutinurad 75 mg and 50 mg achieved significantly higher serum urate target rates than placebo at month 6, with reductions sustained…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.